a novel biologic that inhibits il-4 and il-13 SIGNALING, two of the sources of inflammation in asthma1,a
As add-on maintenance treatment for patients (12+ years) with moderate-to-severe asthma with an eosinophilic phenotype, or with OCS-dependent asthma regardless of phenotype. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.
a The mechanism of dupilumab action in asthma has not been established.

EOS, eosinophils; FEV1, forced expiratory volume in 1 second; MOA, mechanism of action; OCS, oral corticosteroid; OR, odds ratio; SOC, standard of care.


    References:
  1. DUPIXENT Prescribing Information.
  2. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.
  • b With DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood eosinophils ≥300 cells/μL (Trial 1, secondary endpoint).
  • cWith DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107) (Trial 3, secondary endpoint).
  • dAt Week 52 with DUPIXENT 300 mg + SOC (n=277) vs 230 mL improvement with placebo + SOC (n=142) in subjects with baseline blood eosinophils ≥300 cells/μL (Trial 2, secondary endpoint).
  • eBased on AQLQ(S) responder rate at Week 52 with DUPIXENT 200 mg + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (Trial 2, secondary endpoint).
  • fAQLQ(S): Asthma Quality of Life Questionnaire, Standardized Version, a patient-reported measure of asthma-related quality of life. Higher scores indicate better quality of life; a global score is calculated ranging from 1 to 7. The meaningful clinically important difference is 0.5.1